RVYL tumbles as Ryvyl Q4 loss widens dramatically EPS miss of 899 sparks investor concerns The one metric that defines Clorox CLX success Market Focus 20260507 Nektar Therapeutics NKTR Top Gainer Nektar Therapeutics beats EPS estimates by 295